Synergy Pharmaceuticals, Inc. (SGYP) Files Form 4 Insider Selling : John P Brancaccio Sells 2,518 Shares

Synergy Pharmaceuticals, Inc. (SGYP): John P Brancaccio , director of Synergy Pharmaceuticals, Inc. sold 2,518 shares on Sep 19, 2016. The Insider selling transaction was reported by the company on Sep 21, 2016 to the Securities and Exchange Commission. The shares were sold at $5.76 per share for a total value of $14,503.68 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 20, 2016, & Co. Inc. Paulson (10% owner) sold 3,473,713 shares at $5.61 per share price.On Sep 16, 2015, Bernard Denoyer (Senior Vice President, Finance) sold 10,000 shares at $7.50 per share price.Also, On Sep 14, 2015, Alan Joslyn (director) sold 13,754 shares at $7.23 per share price.

Shares of Synergy Pharmaceuticals Inc (SGYP) ended Tuesday, Sep 21, 2016 session in red amid volatile trading. The shares closed down -0.01 points or -0.18% at $5.55 with 37,06,677 shares getting traded. Post opening the session at $5.7, the shares hit an intraday low of $5.53 and an intraday high of $5.7 and the price vacillated in this range throughout the day. The company has a market cap of $996 M and the number of outstanding shares has been calculated to be 17,94,46,970 shares. The 52-week high of Synergy Pharmaceuticals Inc is $7.44 and the 52-week low is $2.5.

Synergy Pharmaceuticals Inc Money Flow Index Chart

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company’s platform technology is based on the naturally occurring human GI peptide uroguanylin a regulator of normal GI physiology. The Company’s products include plecanatide SP-333 and FV-100. The Company’s lead product is plecanatide a guanylate cyclase C (GC-C) receptor agonist designed to treat GI disorders primarily chronic idiopathic constipation (CIC) and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist SP-333 for the treatment of opioid induced constipation (OIC) and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Company’s subsidiaries include Synergy Advanced Pharmaceuticals Inc. IgX Ltd and ContraVir Pharmaceuticals Inc.

Leave a Reply

Synergy Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Synergy Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.